EUVIMEDObjevte EUVIMED
Crossref

Adjunctive antipsychotics for MDD differ in efficacy and acceptability

The Brown University Psychopharmacology Update · 2026-09 · 37 (9) · 1-6

DOI: 10.1002/pu.31485 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-08-03.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

A systematic review and network meta‐analysis has found considerable differences in efficacy and acceptability among atypical antipsychotics used as adjunctive treatment for major depressive disorder (MDD). Lumateperone had the greatest effect size for efficacy, and aripiprazole had the highest level of acceptability. Results of the systematic review and meta‐analysis were published online May 6, 2026 in JAMA Psychiatry .

Cite

APA

(2026). Adjunctive antipsychotics for MDD differ in efficacy and acceptability. The Brown University Psychopharmacology Update, 37(9), 1-6. https://doi.org/10.1002/pu.31485

Vancouver

Adjunctive antipsychotics for MDD differ in efficacy and acceptability. The Brown University Psychopharmacology Update. 2026;37(9):1-6. doi:10.1002/pu.31485

BibTeX
@article{euvimed2026,
  title = {Adjunctive antipsychotics for MDD differ in efficacy and acceptability},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {9},
  pages = {1--6},
  doi = {10.1002/pu.31485}
}
Start for free →